Advances in autologous treatment and mobilization in lymphoma
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
HDACs in multiple myeloma: potential benefits in maintenance phase
Novel issues in the combined modality treatment of lymphomas
Is denosumab superior to zoledronic acid in the treatment of bone metastases in MM?